Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novo Nordisk A/S (NVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 129,653,704
  • Shares Outstanding, K 2,443,530
  • Annual Sales, $ 16,967 M
  • Annual Income, $ 5,792 M
  • 36-Month Beta 0.54
  • Price/Sales 7.42
  • Price/Cash Flow 20.07
  • Price/Book 16.64

Price Performance

See More
Period Period Low Period High Performance
1-Month
48.52 +10.78%
on 02/08/18
58.25 -7.73%
on 01/24/18
-4.19 (-7.23%)
since 01/23/18
3-Month
48.52 +10.78%
on 02/08/18
58.37 -7.92%
on 01/23/18
+1.91 (+3.68%)
since 11/22/17
52-Week
32.89 +63.42%
on 03/08/17
58.37 -7.92%
on 01/23/18
+17.97 (+50.22%)
since 02/23/17

Most Recent Stories

More News
Pharma Stock Roundup: AZN's Imfinzi Gets 2nd FDA Nod, MRK to Buy Australian Firm

Key announcements this week included the FDA approval for a second indication of AstraZeneca's (AZN) Imfinzi and an acquisition offer by Merck (MRK).

AZN : 33.98 (+0.86%)
NVO : 53.79 (+1.38%)
VYGR : 28.48 (+10.13%)
MRK : 54.89 (+0.59%)
IONS : 50.79 (+1.82%)
ABBV : 118.47 (+0.77%)
ACOR : 26.00 (-1.52%)
BMY : 67.78 (+2.79%)
Eurozone Beats United States Again: 5 Hot Stock Picks

5 Europe-based stocks to buy as the region scores decade-high growth rate in 2017.

ING : 18.20 (+0.72%)
CMPR : 166.70 (+2.41%)
NVO : 53.79 (+1.38%)
TLND : 42.50 (+1.29%)
ASML : 196.90 (+1.87%)
The Zacks Analyst Blog Highlights: Nordisk, TJX, Cigna, Regeneron and ArcelorMittal

The Zacks Analyst Blog Highlights: Nordisk, TJX, Cigna, Regeneron and ArcelorMittal

TJX : 77.61 (+1.58%)
NVO : 53.79 (+1.38%)
CI : 194.07 (+1.13%)
MT : 35.01 (+0.17%)
REGN : 322.71 (+2.18%)
Top Research Reports for Novo Nordisk, TJX Companies & Cigna

Top Research Reports for Novo Nordisk, TJX Companies & Cigna

TJX : 77.61 (+1.58%)
NVO : 53.79 (+1.38%)
CI : 194.07 (+1.13%)
MT : 35.01 (+0.17%)
REGN : 322.71 (+2.18%)
WMB : 28.68 (+0.42%)
Novo Nordisk A/S: Ozempic(R) (semaglutide) approved in the EU for the treatment of type 2 diabetes

Bagsvaerd, Denmark, 9 February 2018 - Novo Nordisk today announced that the European Commission (EC) has granted marketing authorisation for Ozempic(R) (semaglutide) for the treatment of adults with type...

NVO : 53.79 (+1.38%)
Quotidian Technical Highlights on Selected Drug Makers Stocks -- Novo Nordisk, Sucampo Pharma, Synergy Pharma, and Teva Pharmaceutical Industries

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on NVO, SCMP, SGYP, and TEVA which can be accessed for free by signing up to www.wallstequities.com/registration....

SCMP : 18.05 (+0.28%)
NVO : 53.79 (+1.38%)
TEVA : 19.98 (+0.91%)
SGYP : 1.88 (+1.08%)
Novo Nordisk Launches Rebinyn® in the United States for People with Hemophilia B

Novo Nordisk, a global healthcare company, today announced that Rebinyn®, Coagulation Factor IX (Recombinant), GlycoPEGylated, is now available in the United States for the treatment of hemophilia B.

NVO : 53.79 (+1.38%)
Novo Nordisk files annual report with the SEC

Bagsvaerd, Denmark, 8 February 2018 - Novo Nordisk A/S has filed its Annual Report 2017 on Form 20-F for the financial year 2017 with the US Securities and Exchange Commission (SEC), incorporating by reference...

NVO : 53.79 (+1.38%)
Novo Nordisk Launches Ozempic® and Fiasp®, Expanding Treatment Options for Adults with Diabetes

Novo Nordisk today announced the availability of two new diabetes medications, Ozempic® (semaglutide) injection 0.5 mg or 1 mg and Fiasp® (insulin aspart injection) 100 Units/mL at pharmacies across...

NVO : 53.79 (+1.38%)
Foreign Stock Roundup: RDS.A & AZN Impress, NVO & BABA Disappoint

Losses on Wall Street and falling bond yields weighed on global markets this week.

BABA : 193.07 (+2.29%)
AAPL : 175.52 (+1.75%)
AZN : 33.98 (+0.86%)
BBD : 12.35 (+0.65%)
NVO : 53.79 (+1.38%)
RDS.A : 63.92 (+1.06%)
FBR : 18.67 (-0.53%)
ITUB : 16.31 (+0.74%)
RHHBY : 29.7400 (-0.37%)
DB : 16.43 (-0.12%)
BSBR : 11.63 (+2.47%)
HMC : 36.14 (+1.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural...

See More

Key Turning Points

2nd Resistance Point 54.18
1st Resistance Point 53.62
Last Price 53.79
1st Support Level 52.68
2nd Support Level 52.30

See More

52-Week High 58.37
Last Price 53.79
Fibonacci 61.8% 48.64
Fibonacci 50% 45.63
Fibonacci 38.2% 42.62
52-Week Low 32.89

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.